PROVIDENCE, R.I. — EpiVax Inc., a vaccine development and immune engineering company based in Providence, R.I., has announced it is part of collaboration supported by a $5.8 million award from the National Institutes of Health (NIH) to develop a new type of vaccine against H7N9 avian influenza.
Scientists using bioinformatics and molecular modeling techniques will engineer the H7N9 hemagglutinin (HA) to resemble seasonal flu, which could help trigger immune memory and help conventional HA-oriented flu vaccine protect against H7N9, the company said.
The five-year program will also include scientists from the University of Massachusetts Medical School. . .
Register or Login to keep reading
Thank you for your interest in accessing the complete content. To continue reading, please register for free. By registering, you'll gain full access to our valuable resources, updates, and insights.
If you already have an account please Log In.
